In Silico and In Vitro Search for Dual Inhibitors of the Trypanosoma brucei and Leishmania major Pteridine Reductase 1 and Dihydrofolate Reductase
-
Published:2023-11-10
Issue:22
Volume:28
Page:7526
-
ISSN:1420-3049
-
Container-title:Molecules
-
language:en
-
Short-container-title:Molecules
Author:
Possart Katharina1, Herrmann Fabian C.1, Jose Joachim2ORCID, Schmidt Thomas J.1ORCID
Affiliation:
1. University of Muenster, Institute for Pharmaceutical Biology and Phytochemistry (IPBP), PharmaCampus, Corrensstrasse 48, D-48149 Muenster, Germany 2. University of Muenster, Institute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, Corrensstrasse 48, D-48149 Muenster, Germany
Abstract
The parasites Trypanosoma brucei (Tb) and Leishmania major (Lm) cause the tropical diseases sleeping sickness, nagana, and cutaneous leishmaniasis. Every year, millions of humans, as well as animals, living in tropical to subtropical climates fall victim to these illnesses’ health threats. The parasites’ frequent drug resistance and widely spread natural reservoirs heavily impede disease prevention and treatment. Due to pteridine auxotrophy, trypanosomatid parasites have developed a peculiar enzyme system consisting of dihydrofolate reductase-thymidylate synthase (DHFR-TS) and pteridine reductase 1 (PTR1) to support cell survival. Extending our previous studies, we conducted a comparative study of the T. brucei (TbDHFR, TbPTR1) and L. major (LmDHFR, LmPTR1) enzymes to identify lead structures with a dual inhibitory effect. A pharmacophore-based in silico screening of three natural product databases (approximately 4880 compounds) was performed to preselect possible inhibitors. Building on the in silico results, the inhibitory potential of promising compounds was verified in vitro against the recombinant DHFR and PTR1 of both parasites using spectrophotometric enzyme assays. Twelve compounds were identified as dual inhibitors against the Tb enzymes (0.2 μM < IC50 < 85.1 μM) and ten against the respective Lm enzymes (0.6 μM < IC50 < 84.5 μM). These highly promising results may represent the starting point for the future development of new leads and drugs utilizing the trypanosomatid pteridine metabolism as a target.
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference40 articles.
1. (2023, June 22). Neglected Tropical Diseases—GLOBAL. Available online: https://www.who.int/health-topics/neglected-tropical-diseases#tab=tab_1. 2. Herrmann, F.C. (2016). In Silico-Identifikation und In Vitro-Evaluation Natürlicher Inhibitoren Diverser Therapierelevanter Zielenzyme von Humanpathogenen Eukaryoten der Gattungen Trypanosoma, Leishmania und Plasmodium. [Ph.D. Thesis, University of Münster]. 3. Herrmann, F.C., Sivakumar, N., Jose, J., Costi, M.P., Pozzi, C., and Schmidt, T.J. (2017). In silico Identification and In vitro Evaluation of Natural Inhibitors of Leishmania major Pteridine Reductase I. Molecules, 22. 4. Possart, K., Herrmann, F.C., Jose, J., Costi, M.P., and Schmidt, T.J. (2021). Sesquiterpene Lactones with Dual Inhibitory Activity against the Trypanosoma brucei Pteridine Reductase 1 and Dihydrofolate Reductase. Molecules, 27. 5. In silico Identification and in vitro Activity of Novel Natural Inhibitors of Trypanosoma brucei Glyceraldehyde-3-phosphate-dehydrogenase;Herrmann;Molecules,2015
|
|